Turn Therapeutics Inc. (Nasdaq: TTRX) is a clinical-stage biotechnology company whose news flow centers on dermatology, advanced wound care, infectious disease therapies, and intranasal vaccine initiatives. Company updates frequently highlight progress in its lead program GX-03, a topical IL-36/IL-31 pathway inhibitor in a phase 2 trial for moderate to severe atopic dermatitis, as well as other late-stage clinical programs in eczema and onychomycosis.
News releases from Turn Therapeutics regularly cover clinical milestones, such as enrollment updates, safety summaries, and timing for interim and topline data from its phase 2 eczema study. Investors and observers can also follow announcements related to its thermostable intranasal vaccine initiative, including stability data for a live, lipid-enveloped vaccine formulated with the PermaFusion platform and the planned in-vivo and in-vitro studies for an intranasal influenza vaccine candidate.
Corporate and strategic developments are another key theme in TTRX news. The company has reported its direct listing on Nasdaq, capital strategy using flexible financing arrangements, and a global supply, development, and license agreement with Medline to develop and commercialize PermaFusion-based products in professional and retail markets. Governance updates, including the appointments of experienced board members and a Vice President of Corporate Communications, also feature prominently.
Turn Therapeutics additionally issues communications on shareholder engagement efforts, such as webinar series and public discussions involving its leadership on topics like healthcare communication and public trust in science. For readers tracking TTRX, this news page offers a centralized view of clinical progress, partnership activity, financing developments, and corporate governance changes over time.
Turn Therapeutics (Nasdaq: TTRX) announced that CEO Bradley Burnam spoke with Dr. Robert Redfield, former CDC director, on Nov 11, 2025 about healthcare communications and restoring public trust in science.
The interview, titled "Redfield’s Warning: Former CDC Director on COVID’s Biggest Casualty-Trust in Science", is available on major podcast platforms, YouTube, and the Turn Therapeutics investor relations website. The conversation emphasizes fact-based science, data-driven public health messaging, and continued dialogue between biotech leaders and public officials.
Dr. Redfield is described as a virologist who led CDC from 2018–2021 and contributed to early HIV research including the Walter Reed staging system and evidence of active HIV replication across disease stages.
Turn Therapeutics (Nasdaq: TTRX) said its topical IL-36/IL-31 inhibitor GX-03 was named one of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online on Nov 11, 2025. The company said GX-03 is the first topical agent targeting IL-36 and demonstrated inhibition of IL-36 alpha, IL-31, IL-4, and IL-36 gamma. Turn described GX-03 as a potential alternative to systemic and injectable therapies for eczema and psoriasis. The company also said it expects to announce topline data from its lead severe eczema program in early 2026.
Patient Care Online is described as a clinical news resource for office-based clinicians covering drug approvals, research commentary, and clinical trial highlights.
Turn Therapeutics (Nasdaq: TTRX) announced on November 4, 2025 the appointment of Andrew Scott as Vice President of Corporate Communications.
Mr. Scott will oversee investor relations, capital markets strategy, and corporate communications, and will support the company’s licensing and partnership initiatives as Turn advances toward the completion of its Phase 2 clinical program. He joins after a 30-year capital markets career, including a Managing Director role at ThinkEquity and prior business development work at Fortress Biosciences, and has helped raise approximately $3 billion across life-sciences transactions.
Turn Therapeutics (Nasdaq: TTRX) on October 30, 2025 announced a global supply, development, and license agreement with Medline to combine Turn's PermaFusion® delivery platform with Medline's scale and distribution.
The collaboration establishes a long-term partnership to develop, manufacture, and commercialize professional and consumer products; financial terms, specific product categories, and timelines are confidential. The company said it will provide updates as joint initiatives progress toward commercialization and as development milestones are achieved.
Turn Therapeutics (Nasdaq: TTRX) provided a shareholder update on October 22, 2025 outlining clinical progress and a flexible capital plan following a dilution-sparing direct listing.
Key items: a $85 million GEM Global Yield agreement provides on-demand financing; the randomized Phase 2 trial of topical GX-03 for moderate to severe eczema is ~25% complete with >1,000 confirmed study product applications and a blinded aggregate safety summary reporting no safety or tolerability concerns to date; topline GX-03 results are anticipated in 2026. Turn also plans in‑vivo studies for a thermostable intranasal vaccine initiative in Q4 2025. The company hosted a shareholder webinar on October 22, 2025 at 2:00 PM ET.
Turn Therapeutics (Nasdaq: TTRX) launched a shareholder communications initiative including a recurring webinar series and a Founder Blog by CEO Bradley Burnam.
The first live webinar is scheduled for October 22, 2025 at 2:00 PM ET via webcast; recordings and materials will be posted to the investor relations website immediately after each session. The Founder Blog will share ongoing company updates, research insights, and perspectives, with additional blog details to be announced later this week.
Turn notes three FDA clearances for its wound and dermatology formulations and ongoing late-stage clinical programs in eczema and onychomycosis.
Turn Therapeutics (NASDAQ:TTRX) announced on October 15, 2025 that Kent E. Kester, MD, FACP, FIDSA, FASTMH, has been appointed to its Board of Directors.
Dr. Kester is described as a retired U.S. Army Colonel and an infectious disease physician with senior leadership experience in clinical development, translational medicine, vaccine and anti-infective innovation, and public-private global health collaborations, including service as Commander of the Walter Reed Army Institute of Research. The company said his experience will support late-stage programs, regulatory milestones, governance, and strategic direction as Turn advances its dermatology, wound, and anti-infective therapies.
Turn Therapeutics (NASDAQ:TTRX) appointed Arthur Golden to its Board of Directors effective Oct 14, 2025. Mr. Golden brings corporate governance and legal expertise, including 24 years as a director at Emerson Electric and more than 40 years as a partner and now Senior Counsel at Davis Polk & Wardwell. The company said his experience in M&A, shareholder relations, compliance, and cross-border governance will support oversight as Turn advances its late-stage dermatology, wound, and anti-infective programs.
The CEO framed the hire as strengthening governance, strategic execution, and capital-market navigation during a critical growth inflection for the company.
Turn Therapeutics (NASDAQ:TTRX) announced its common stock will commence trading today, October 8, 2025, on the Nasdaq Capital Market under the ticker TTRX.
The company's Form S-1 was declared effective by the SEC on September 30, 2025. Founder and CEO Bradley Burnam will participate in a Closing Bell ceremony at 4:00 PM ET on October 8, 2025, broadcast live from Nasdaq MarketSite. Financial advisor and legal counsel were named: Clear Street LLC (financial advisor) and Davis Polk and Wardwell (legal counsel).